gabexate has been researched along with Disease Exacerbation in 6 studies
Gabexate: A serine proteinase inhibitor used therapeutically in the treatment of pancreatitis, disseminated intravascular coagulation (DIC), and as a regional anticoagulant for hemodialysis. The drug inhibits the hydrolytic effects of thrombin, plasmin, and kallikrein, but not of chymotrypsin and aprotinin.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Bone metastases from gastric cancer (GC) are considered a relatively uncommon finding; however, they are related to poorer prognosis." | 2.52 | Targeting mast cells in gastric cancer with special reference to bone metastases. ( Ammendola, M; De Sarro, G; Gadaleta, CD; Leporini, C; Marech, I; Oakley, C; Ranieri, G; Russo, E; Sacco, R; Sammarco, G, 2015) |
| "The number of the chronic renal failure (CRF) patients is increasing explosively." | 1.38 | Effect of a serine protease inhibitor on the progression of chronic renal failure. ( Adachi, M; Hayata, M; Kakizoe, Y; Kitamura, K; Miyoshi, T; Mizumoto, T; Morinaga, J; Onoue, T; Sakai, Y; Shiraishi, N; Tomita, K; Uchimura, K; Ueda, M; Yamazoe, R, 2012) |
| "Gabexate mesilate treatment significantly decreased the elevation of serum transaminase levels and improved liver histology 24 h after the administration of CCl4 (0." | 1.33 | Gabexate mesilate, a synthetic protease inhibitor, attenuates carbon tetrachloride-induced liver injury in rats. ( Goto, T; Kataoka, E; Lin, JG; Mikami, K; Miura, K; Ohshima, S; Segawa, D; Shibuya, T; Watanabe, D; Watanabe, S; Yoneyama, K, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Giovane, RA | 1 |
| Rezai, S | 1 |
| Cleland, E | 1 |
| Henderson, CE | 1 |
| Mollica, V | 1 |
| Rizzo, A | 1 |
| Massari, F | 1 |
| Ueda, M | 2 |
| Uchimura, K | 2 |
| Narita, Y | 1 |
| Miyasato, Y | 1 |
| Mizumoto, T | 2 |
| Morinaga, J | 2 |
| Hayata, M | 2 |
| Kakizoe, Y | 2 |
| Adachi, M | 2 |
| Miyoshi, T | 2 |
| Shiraishi, N | 2 |
| Kadowaki, D | 1 |
| Sakai, Y | 2 |
| Mukoyama, M | 1 |
| Kitamura, K | 2 |
| Leporini, C | 1 |
| Ammendola, M | 1 |
| Marech, I | 1 |
| Sammarco, G | 1 |
| Sacco, R | 1 |
| Gadaleta, CD | 1 |
| Oakley, C | 1 |
| Russo, E | 1 |
| De Sarro, G | 1 |
| Ranieri, G | 1 |
| Yamazoe, R | 1 |
| Onoue, T | 1 |
| Tomita, K | 1 |
| Mikami, K | 1 |
| Goto, T | 1 |
| Miura, K | 1 |
| Ohshima, S | 1 |
| Yoneyama, K | 1 |
| Lin, JG | 1 |
| Watanabe, D | 1 |
| Segawa, D | 1 |
| Kataoka, E | 1 |
| Shibuya, T | 1 |
| Watanabe, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy of Gabapentin for Post-Covid-19 Olfactory Dysfunction[NCT05184192] | Phase 2 | 50 participants (Anticipated) | Interventional | 2022-01-10 | Enrolling by invitation | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for gabexate and Disease Exacerbation
| Article | Year |
|---|---|
Current pharmacological modalities for management of novel coronavirus disease 2019 (COVID-19) and the rationale for their utilization: A review.
Topics: Adenosine Monophosphate; Alanine; Angiotensin-Converting Enzyme 2; Antibodies, Monoclonal, Humanized | 2020 |
Targeting mast cells in gastric cancer with special reference to bone metastases.
Topics: Animals; Antigens, CD34; Benzamides; Benzamidines; Bone and Bones; Bone Neoplasms; Bone Resorption; | 2015 |
4 other studies available for gabexate and Disease Exacerbation
| Article | Year |
|---|---|
The pivotal role of TMPRSS2 in coronavirus disease 2019 and prostate cancer.
Topics: Androgens; Angiotensin-Converting Enzyme 2; Betacoronavirus; Carcinogenesis; Coronavirus Infections; | 2020 |
The serine protease inhibitor camostat mesilate attenuates the progression of chronic kidney disease through its antioxidant effects.
Topics: Animals; Antihypertensive Agents; Antioxidants; Blood Pressure; Creatinine; Disease Progression; Est | 2015 |
Effect of a serine protease inhibitor on the progression of chronic renal failure.
Topics: Animals; Creatinine; Disease Progression; Esters; Gabexate; Guanidines; Kidney; Kidney Failure, Chro | 2012 |
Gabexate mesilate, a synthetic protease inhibitor, attenuates carbon tetrachloride-induced liver injury in rats.
Topics: Animals; Carbon Tetrachloride; Chemical and Drug Induced Liver Injury; Disease Models, Animal; Disea | 2005 |